

# Structural insights into Rift Valley fever virus replication machinery

**Zhongzhou Chen** (✉ [chenzhongzhou@cau.edu.cn](mailto:chenzhongzhou@cau.edu.cn))

China Agriculture University <https://orcid.org/0000-0003-1319-9664>

**Hong-Wei Wang**

Tsinghua University <https://orcid.org/0000-0001-9494-8780>

**Xue Wang**

China Agriculture University

**Cuixia Hu**

Tsinghua University

**Jia Wang**

Tsinghua University

**Xiaofei Dong**

China Agriculture University

**Jie Xu**

Tsinghua University

**Xiaorong Li**

China Agricultural University

**Manfeng Zhang**

Genome Analysis Laboratory of the Ministry of Agriculture, Agricultural Genomics Institute at Shenzhen,  
Chinese Academy of Agricultural Sciences

**Hongyun Lu**

China Agriculture University

**Wei Ye**

Fourth Military Medical University

**Fanglin Zhang**

Fourth Military Medical University

**Wei Wu**

China Agricultural University

---

## Article

**Keywords:** Rift Valley fever virus, RNA-dependent RNA polymerase, structure, replication

**Posted Date:** April 15th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-398449/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

## **Manuscript title: Structural insights into Rift Valley fever virus replication machinery**

Xue Wang<sup>1,4</sup>, Cuixia Hu<sup>2,4</sup>, Wei Ye<sup>3</sup>, Jia Wang<sup>2</sup>, Xiaofei Dong<sup>1</sup>, Jie Xu<sup>2</sup>, Xiaorong Li<sup>1</sup>, Manfeng Zhang<sup>1</sup>, Hongyun Lu<sup>1</sup>, Fanglin Zhang<sup>3</sup>, Wei Wu<sup>1</sup>, Hong-Wei Wang<sup>2,\*</sup> and Zhongzhou Chen<sup>1,\*</sup>

<sup>1</sup> State Key Laboratory of Agrobiotechnology and Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Biological Sciences, China Agricultural University, Beijing, China, 100193

<sup>2</sup> Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China, 100084

<sup>3</sup> Department of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China

<sup>4</sup> These authors contributed equally: Xue Wang, Cuixia Hu.

\* To whom correspondence should be addressed:

Zhongzhou Chen

E-mail: [chenzhongzhou@cau.edu.cn](mailto:chenzhongzhou@cau.edu.cn)

Hong-Wei Wang

E-mail: [hongweiwang@tsinghua.edu.cn](mailto:hongweiwang@tsinghua.edu.cn) (H.-W.W.)

### Abstract

Rift Valley fever virus (RVFV) belongs to the order *Bunyavirales* and is the type species of genus *Phlebovirus*, which accounts for over 50% of family *Phenuviridae* species. RNA-dependent RNA polymerase (L protein) is responsible for facilitating the replication and transcription of the virus. We report two cryo-EM RVFV L protein structures at 3.6 Å and 3.8 Å resolution in the presence and absence of RNA, respectively. In this first L protein structure of genus Phlebovirus, viral RNA induces considerable conformational changes of the polymerase. The RVFV L protein priming loop is distinctly different from those of other L proteins and undergoes large movements related to its replication elongation role. Structural and biochemical analyses indicate that a single template can initiate RNA replication, which is notably enhanced by 5' viral RNA. These findings advance our understanding of RNA synthesis mechanism and provide a basis for antiviral inhibitor development.

**KEYWORDS:** Rift Valley fever virus; RNA-dependent RNA polymerase; structure; replication

38 **INTRODUCTION**

39 The order *Bunyavirales*, negative-sense, single-stranded RNA virus, is divided into twelve  
40 families (*Arenaviridae*, *Cruliviridae*, *Fimoviridae*, *Hantaviridae*, *Leishbuviridae*, *Mypoviridae*,  
41 *Nairoviridae*, *Peribunyaviridae*, *Phasmaviridae*, *Phenuiviridae*, *Tospoviridae*, and *Wupedeviridae*)  
42 (<https://talk.ictvonline.org/taxonomy/>), including over 300 identified species <sup>1</sup>. The order  
43 *Bunyavirales* can infect plants, animals, and humans, posing a serious threat to agriculture, animal  
44 husbandry, human life, and property. For example, Tomato spotted wilt virus can infect more than  
45 1,000 plant species, Hantaan orthohantavirus and Lassa mammarenavirus cause severe  
46 hemorrhagic fevers with a mortality rate of up to 50%, Crimean-Congo hemorrhagic fever virus  
47 also causes severe hemorrhagic fever in humans with mortality rates of up to 30% <sup>2,3</sup>. Rift Valley  
48 fever virus (RVFV) belongs to the order *Bunyavirales*, family *Phenuiviridae*, genus *Phlebovirus*  
49 (<https://talk.ictvonline.org/taxonomy/>), and is one of the most prominent and well-known  
50 bunyaviruses <sup>4</sup>. The genus *Phlebovirus* includes 60 species and accounts for more than half of the  
51 family *Phenuiviridae* species (117 species). RVFV, the type species of this genus, is a zoonosis,  
52 leading to severe infections in animals and humans and significant economic losses.

53

54 RVFV was first isolated in Kenya in 1931 by Daubney et al. through inoculating lambs with  
55 the serum from a moribund sheep <sup>5</sup>. Rift Valley fever (RVF) is widespread in Africa, and multiple  
56 outbreaks have been recorded in Africa and the Arabian Peninsula in the 21st century. Recent  
57 outbreaks in a French overseas department and some seropositive and imported cases in Turkey,  
58 Libya, and China have raised concerns that RVF could extend to other parts of the world, which  
59 poses a serious threat to global health and economics <sup>6-11</sup>. RVFV is transmitted among ruminants  
60 by bites from mosquitos mainly of the *Aedes* and *Culex* genera, or by direct contact with body  
61 fluids of viremic animals <sup>12</sup>. RVFV is classified as a category A high priority pathogen by the  
62 National Institute of Allergy and Infectious Diseases and virus handling requires high- or  
63 maximum-containment facilities, such as a biosafety level 3 enhanced (BSL-3E) or BSL-4  
64 laboratory <sup>13</sup>. RVFV leads to severe disease in livestock, with up fatality rates of up to 70% in  
65 young animals and as high as 20%-30% in adult ruminants. In addition, infected pregnant animals  
66 undergo spontaneous abortion at an alarmingly high rate, in the range of 40–100% <sup>14</sup>. After being  
67 infected with RVFV, humans may experience generalized fatigue, low-grade fever, headache,  
68 photophobia, and joint pains. Some patients infected with RVFV will develop encephalitis,  
69 retinopathy, or disseminated intravascular coagulation leading to hemorrhage and even death, with  
70 a case fatality rate of approximately 20% <sup>11</sup>. The cross-border movement of goods and animals  
71 means that there is now a threat of RVFV dissemination to Asia and Europe <sup>15</sup>.


72

73 RVFV has a single-stranded, tripartite RNA genome, composed of L, M, and S segments. The  
74 large negative-sense L RNA segment encodes a single-polypeptide L protein and the  
75 negative-sense M RNA segment encodes the glycoprotein precursor. The S segment adopts an  
76 ambisense strategy for expressing NSs and N proteins <sup>16</sup>. The RVFV viral genome is wrapped by  
77 the N proteins and the conserved 3' and 5' ends of the genomic RNA (vRNA) are bound to L  
78 protein, resembling the influenza virus <sup>17,18</sup>. The L protein is a multifunctional enzyme that  
79 catalyzes genome replication and viral gene transcription, which are initiated *de novo* by  
80 prime-and-realign and a cap-snatching mechanisms, respectively <sup>19</sup>.

81

82 To date, precautions to avoid new RVFV outbreaks mostly rely on weather monitoring, and no  
 83 specific drugs or licensed vaccines are available to treat or prevent infection<sup>20</sup>. Moreover, no  
 84 genus RNA-dependent RNA polymerase (RdRp) *Phlebovirus* structures have been reported. To  
 85 understand the role of L protein in the viral life cycle and identify a feasible drug target, we solved  
 86 two RVFV polymerase structures, with or without RNA. These are the first genus *Phlebovirus* L  
 87 structures to be described. Cryogenic electron microscopy (cryo-EM) revealed RVFV L structures  
 88 at 3.6 Å or 3.8 Å resolution, in the presence or absence of RNA, respectively, and was used to  
 89 build a molecular model for the core polymerase domain. These structures guided the elucidation  
 90 of the mechanism of viral replication and transcription. Using biochemical assays we verified the  
 91 novel endonuclease activity and polymerase activity of the RVFV L protein. The RVFV L protein  
 92 endonuclease activity has a preference toward MnCl<sub>2</sub> and has polymerase activity in the presence  
 93 of only template RNA or both template and allosteric activator RNA.  
 94

## 95 RESULTS



96  
 97

### 98 **Figure 1. *In vitro* enzymatic activity assays**

- 99 (A) SDS-PAGE profile of Rift Valley fever virus (RVFV) L protein.  
 100 (B) Size-exclusion chromatogram of RVFV L protein. Absorbance curves for the sample at  
 101 wavelengths of 260 nm and 280 nm.  
 102 (C) Endonuclease activity assay. RVFV L protein (0.06 μM) was incubated with 0.45 μM of  
 103 fluorescently labeled 30 nt PolyA RNA substrate at 30°C for 40 min in the presence of 10, 25,

104 or 50 mM MnCl<sub>2</sub> or CaCl<sub>2</sub>. Reactions without protein, in the presence of EDTA or the known  
105 endonuclease-specific inhibitor 2,4-dioxo-4-phenylbutanoic acid (DPBA), were negative  
106 controls. All input is shown as red arrows in Figure C, D, and E.

107 (D) *In vitro* polymerase activity assay. The endonuclease and polymerase inactivation site double  
108 mutant (D111A/D1133A) was added in the left lane as a negative control. Mutant (D111A)  
109 was added in the middle and right lanes. These three lanes were incubated with the conserved  
110 5' 20 nt of the M segment or/and a 20 nt template RNA named RNA\* (5' M:  
111 5'-ACACAAAGACGGUGCAUUA-3', RNA\*: 5'-UGUGUUUCUGGCCACGUUGA-3').  
112 Replication products were detected by fluorescence (fluorescein-12-UTP).

113 (E) Effect of metal ions (Mn<sup>2+</sup> or Mg<sup>2+</sup>) and reducing agent (DTT or TCEP  
114 (Tris(2-carboxyethyl)phosphine)) on *de novo* RNA synthesis by endonuclease inactivation site  
115 mutant (D111A). The assay was performed with 5 mM MnCl<sub>2</sub>/MgCl<sub>2</sub> and 2.5 mM DTT/TCEP  
116 for 40 min at 30°C.

117


### 118 Enzymatic properties of RVFV L protein *in vitro*

119 After extensive screening, we successfully constructed and expressed the full-length L protein  
120 using the *Pichia pastoris* expression system. Full-length L protein existed as a monomer in  
121 solution ([Figure 1A](#), [Figure 1B](#)). *In vitro* endonuclease activity experiments revealed that the L  
122 protein, but not the endonuclease site mutant (D111A), had strong endonuclease activity in the  
123 presence of MnCl<sub>2</sub> ([Supplementary Figure S1A](#)). Using 30 nt polyA as an RNA substrate, the L  
124 protein polymerase had ion-concentration dependent endonuclease activity in the presence of  
125 MnCl<sub>2</sub>, but no activity in the presence of CaCl<sub>2</sub> ([Figure 1C](#), [Supplementary Figure S1](#))<sup>21,22</sup>. To  
126 visualize the *de novo* synthesis of viral RNA, we tested the ability of the purified RVFV L protein  
127 to incorporate fluorescent nucleotides *in vitro*. To prevent RNA degradation during the experiment,  
128 we used the D111A endonuclease site mutant and tested its RNA replication activity. We added  
129 fluorescein-12-UTP into the *in vitro* replication reaction system as the substrate, and monitored the  
130 RNA synthesis products by electrophoresis on 20% polyacrylamide gels containing 7 M urea.  
131 Compared with the D111A/D1133A negative control mutant, which lacks polymerization activity,  
132 a clear replication product was produced by the D111A mutant ([Figure 1D](#)).

133

134 Examination of the synthesized products revealed that most were dinucleotides, and several  
135 oligonucleotide bands were also observed. Together, these results show that RVFV L protein can  
136 produce oligonucleotides using nucleotides with large modifications, such as fluorescein, as the  
137 substrate. This differs from the Vesicular Stomatitis Virus L protein, which can only incorporate  
138 nucleotides with smaller modifications into viral RNA<sup>23</sup>. This result illustrates that the active  
139 center of the RVFV L protein is larger than that of the Vesicular Stomatitis Virus L protein. We  
140 further tested how Mg<sup>2+</sup> and Mn<sup>2+</sup> metal ions affected RVFV L protein polymerase activity in the  
141 presence of different reducing agents (DTT or TCEP). Urea PAGE analysis showed that the type  
142 of reducing agent did not significantly affect RVFV L protein polymerase activity. However,  
143 RVFV L protein polymerase activity was stronger in the presence of MnCl<sub>2</sub> than in the presence of  
144 MgCl<sub>2</sub> ([Figure 1E](#)). This result contrasts with that reported for severe fever with thrombocytopenia  
145 syndrome virus (SFTSV) L protein, the structure of which revealed an active Mg<sup>2+</sup>-coupled  
146 polymerase center<sup>21,24</sup>. Interestingly, the RVFV L protein was also capable of replicating RNA in  
147 the presence of only one template RNA ([Figure 1D](#)). Therefore, the RVFV L protein can

148 incorporate a nucleotide into a nucleotide/oligonucleotide in the absence of 5' vRNA. This activity  
 149 is notably enhanced by the addition of 5' vRNA. This is different from the replication mode of  
 150 most bunyaviruses that need both 5' RNA and 3' RNA for successful replication. To explore the  
 151 mechanism of this unique RVFV L protein property we decided to reveal the RVFV L protein  
 152 structure.



153

154 **Figure 2. Overall structure of the Rift Valley fever virus (RVFV) L<sub>RNA</sub> protein and conserved**

155 **motifs**

- 156 (A) Schematic representation of the monomeric RVFV L<sub>RNA</sub> protein domain structure.  
157 (B) Cartoon representation of the RVFV L<sub>RNA</sub> protein. The structure is colored by domains using  
158 the same color code as in (A). 3<sub>10</sub> helices are colored in gray.  
159 (C) The RVFV L<sub>RNA</sub> protein B-factor map. A larger radius and red color represent high B-factor  
160 values and a smaller radius and blue color represent low B-factor values.  
161 (D) The arrangement of the conserved RdRp motifs in the RVFV active site colored in red, green,  
162 blue, purpleblue, yelloworange, magenta, forest, and teal for motifs A–H, respectively.

163

164 **Overall RVFV L protein structure**

165

166 We performed single particle cryo-EM analysis of the RVFV L protein and obtained two 3D  
167 reconstructions at 3.6 and 3.84 Å resolution in the presence and absence of RNA, respectively  
168 ([Supplementary Figures S2–S6](#), [Supplementary Table S1](#)). Our solved L<sub>RNA</sub> structure had ~1400  
169 residues, corresponding to the PA-C, PB1, and PB2 N-terminus of influenza virus <sup>17</sup> ([Figure 2A](#)).  
170 The L protein was co-purified with the partially dsRNA formed by the 3' and 5' conserved RNA  
171 genome ends (5' vRNA 5'-GGUGCA-3' and 3' vRNA 3'-UGUGUUUCUGGCCACGU-5')  
172 ([Supplementary Figure S7](#)), similar to that described for La Crosse encephalitis virus (LACV) <sup>25,26</sup>.  
173 The overall shape of the L<sub>RNA</sub> structure resembled a figure-“6” ([Supplementary Figure S2F](#)). The  
174 dimensions of the RVFV L<sub>RNA</sub> protein structure are about 85 Å x 75 Å x 95 Å ([Figure 2B](#)).  
175 Moreover, an additional endonuclease domain was solved in the L<sub>apo</sub> structure. The RVFV L<sub>apo</sub>  
176 cryo-EM density map contains the endonuclease domain, RdRp domain, and a short lariat, while  
177 the RVFV L<sub>RNA</sub> contains the RdRp domain and a longer lariat.

178

179 The first domain, at the L<sub>apo</sub> protein N-terminus, is the endonuclease domain (residues 1–214)  
180 ([Supplementary Figure S8](#)). This domain plays an essential role in cleaving 5' m7G caps from host  
181 mRNAs during the cap-snatching process. These free caps are subsequently used as primers for  
182 genome transcription <sup>14,27</sup>. Then a linker domain (residues 215–283) wraps around the core  
183 structure domain, connecting the endonuclease domain to the three core lobe domains (residues  
184 284–322, 441–506, 599–760) ([Figure 2B](#)). The fingers domain (residues 760–858, 874–918,  
185 925–954, 999–1035, 1063–1088) displays a “sandwich” shape, comprised of upper and lower  
186 α-helix layers with a β-sheet in the middle ([Figure 2B](#)). The catalytic center of RdRp is constituted  
187 of fingers, thumb, and palm domains. The thumb domain (residues 1202–1318) is involved in the  
188 formation of the template entry channel to help stabilize initial NTPs binding to the template.  
189 Moreover, the key residues of the thumb domain can promote template translocation following the  
190 first condensation reaction through conformational rearrangement <sup>28</sup>. In brief, the fingers, palm,  
191 and thumb domains ([Supplementary Figure S9](#)) probably collaborate to promote vRNA template  
192 and NTP binding. Furthermore, both L<sub>apo</sub> and L<sub>RNA</sub> structures have an additional C-terminal lariat,  
193 which contains an α-helix and a loop, and interacts with the linker, palm, and core lobe domains.  
194 The C-terminal lariat (residues 1963–1990) in the L<sub>RNA</sub> structure is longer than that in the L<sub>apo</sub>  
195 structure ([Figure 2A](#), [2B](#), [Supplementary Figure S8](#)). The C-terminal lariat circles the large  
196 globular core and folds back to stabilize the fingers' structure. In summary, the active center of the  
197 L protein polymerase is relatively stable and conservative, while the structures of the thumb ring  
198 and bridge regions are flexible ([Figure 2C](#)).


199

200 **Conserved motifs of RdRp**

201

202 Common and unique features of viral RNA-dependent polymerase motifs (motifs A-F) that  
203 contain key residues for the enzymatic function have been identified in many RNA-dependent  
204 polymerases<sup>29</sup>. Like L proteins from many RNA viruses, RVFV L protein has six conserved  
205 structural motifs (motifs A-F) that cooperate with viral RNA template, NTPs, and metal ions to  
206 promote the condensation of nucleotide triphosphates ([Figure 2D](#)). RVFV L protein also has two  
207 single-stranded negative-sense RNA virus specific motifs, G and H ([Figure 2D](#)). Motif G  
208 (668-QTIARYIIME-677) is located in the core lobe domain and consists of an  $\alpha$ -helix, the  
209 conserved Arg672 of which can participate in genome replication and transcription by interacting  
210 with the priming NTPs. Motif H (1045-HRELDI-1050) is located in the fingernode domain and  
211 consists of a loop. Motifs A to E are within the palm subdomain while Motif F  
212 (913-HICLFFKKQQHGLREIYV-930), composed of two  $\beta$ -strands trapping a loop, constitutes  
213 part of the fingertips ([Figure 2D](#)). Motif A (984-WTCATSDDARKWN-996) connects the palm  
214 and fingers domains, and contains one of the invariant catalytic Asp991 residues present both in  
215 DNA and RNA polymerases. The conserved Lys994 in RdRps of single-stranded negative-sense  
216 RNA viruses allows them to use manganese instead of magnesium as the cofactor ion, which is  
217 consistent with our activity assay results ([Figure 1E](#)). Trp995 of Motif A sits in a strategic position  
218 where it can maintain L protein structural stability. Motif B has a conservative Gly1087 at a  
219 position for the loop to change conformation, which allows the N-terminal loop to bind to the  
220 RNA template. Motif C is composed of a  $\beta$ -sheet-loop- $\beta$ -sheet structure, with the conserved loop  
221 region sequence (1132-SDD-1134) forming the active center of RdRp. Motif D consists of an  
222  $\alpha$ -helix and a loop, forming a structural scaffold to change RdRp's conformation when a correct  
223 nucleotide is bound<sup>30</sup>. Motif E (1185-VMEYNSEFYF-1194) is located between the palm and  
224 thumb domains and consists of a  $\beta$ -hairpin structure ([Figure 2D](#)), which works in the correct  
225 positioning of the 3'OH primer end<sup>29</sup>. These motifs and functional regions participate in the most  
226 critical steps for the correct recognition and incorporation of ribonucleotides.

227



228

229 **Figure 3. The fingertips loops of machupo virus (MACV) L<sub>apo</sub>, LACV L complex, apo FluC  
230 polymerase, Rift Valley fever virus (RVFV) L<sub>apo</sub>, and RVFV L<sub>RNA</sub>**

231 The B-factor maps for (A) MACV (PDB 6KLD), (B) LACV (PDB 6Z8K), (C) Influenza C  
232 (FluC) (PDB 5D98), (D) RVFV L<sub>apo</sub>, (E) RVFV L<sub>RNA</sub>. (A, B, E) Fingertips are conservative, while  
233 FluC's and LACV's fingertips are unstable, and their replication process requires 5' RNA.  
234 (F) Interaction of residues between fingertips and finger extension. The residue on the fingertips  
235 and the finger extension are colored green and yellow, respectively.

236


### 237 The fingertips of RVFV L protein

238

239 The fingertips domain (Figure 3), mostly composed of the conserved motif F, extends from the  
240 fingers domain to the thumb domain, and is located directly above RdRps catalytic center.  
241 According to previous reports, during the process of NTPs binding to RdRp, the positively  
242 charged Lys and Arg side chain residues in the fingertips domain can interact with the triphosphate  
243 moiety, which also interacts with both divalent metal ions in the active center (Supplementary  
244 Figure S10)<sup>31</sup>. Moreover, the fingertips domain can bind 5' viral RNA by basic residues<sup>17,25</sup>.  
245 Based on the RVFV L protein structural analysis, we identified that the key residues (Lys918,  
246 Arg926) (Supplementary Figure S10E) for its vitality are positioned in the middle loop region,  
247 right at the junction of the template entry channel and NTP entry channel (Supplementary Figure  
248 S11). Therefore, it is reasonable to consider that the fingertips domain is crucial for binding both  
249 template and NTPs. The previously reported structure of the apo FluCPol harbors highly unstable  
250 fingertips (Figure 3C), whereas the same region in the 5' vRNA-bound FluAPol and FluBPol  
251 structure is stable<sup>17,32</sup>. For the LACV (order *Bunyavirales*) L protein<sup>25</sup>, 5' vRNA induces  
252 conformational changes of the fingertips and the adjacent finger extension, further stabilizing them.  
253 Similarly, the fingertips (motif F) of RVFV L protein and the associated finger extension in RVFV  
254 apo L protein are disordered, but both are highly stable after nucleic acid addition, even though  
255 they do not directly bind to nucleic acid (Figure 3D and E and Movie S1). Moreover, the longer  
256 C-terminal lariat solved in the L<sub>RNA</sub> structure further stabilized the fingers' structure. The finger

extension is oriented in a conformation that provides enough space to hold the fingertip. Residues Tyr760, Lys762, Asn763, and Glu766 (finger extension domain) are highly conserved and have especially strong interactions with the residues (Lys918, Lys919, Gln920, Gln921) in the fingertips domain (Figure 3F).

261



262

#### Figure 4. Conservation analysis for RVFV L protein

263 (A) Sequence conservation analysis. The left figure displayed in surface mode is positioned at the same view as the middle figure. Two different views of the Rift Valley fever virus (RVFV) L protein displayed in ribbon mode and colored based on the residue conservation among family *Phenuiviridae*. The bottom color code bar is from low conservation (cyan) to high conservation (purple). Figures are colored using the Consurf server (<http://consurf.tau.ac.il/2016/>) based on a multiple sequence alignment including the sequences of Tapara virus (YP\_009346035), Toros virus (YP\_009246447), Arumowot virus (YP\_009010958.1), Adana virus (YP\_009227127.1), SFTSV (YP\_006504091.1), Uriurana virus (YP\_009346036.1), Punta Toro virus (YP\_009512941.1), Anhangaa virus (API68876.1), and Munguba virus (YP\_009346010.1).

264 (B) Sequence conservation in the putative priming loop.

265 (C) The priming loop and connecting regions are shown as ribbons colored in green (RVFV) and yellow (SFTSV and PDB 6L42). Two glycine residues (Gly1344 and Gly1345), which are 266 important for an early stage of RNA synthesis, are shown as sticks.

267 (D) Structural demonstration shows the interaction sites of the priming loop (green) and thumb 268 (cyan) and thumb ring domains (yellow).

269

#### 270 Conservation analysis for RVFV L protein


282

We performed sequence alignment of L proteins from a set of ten representative viruses from the family *Phenuiviridae* and analyzed the conservation differences among the various domains<sup>33</sup>. The most conserved regions were the unique motifs A–F of RNA viruses (Figure 4A, Supplementary Figure S12). Based on this sequence alignment, and conservation analysis of the overall sequence of the polymerase on the Consurf website, the residues on the polymerase surface were identified as variable and the residues around the polymerase active center and the four access channels (Figure 5) were highly conserved, and corresponded to the motifs A–F (Figure 4A). The conserved residues around the channels were mainly positively charged residues, reflecting their roles in nucleic acids interaction during viral genome replication and transcription.

292

The priming loop (residues 1319–1358) is a fundamental element that generally stabilizes the first ‘priming’ nucleotide of the product during replication initiation, but is not essential for internal initiation and transcription<sup>34</sup>. The priming loop structure is missing in the pre-initiation structure ( $L_{apo}$  protein) (Supplementary Figure S11A). Interestingly, the addition of RNA stabilizes the conformation of the priming loop, revealing its role in replication (Supplementary Figure S11B). MEME-ChIP analysis revealed that the two glycine residues (Gly1344 and Gly1345) at the tip of the priming loop are conserved<sup>35,36</sup>, and structural comparison with SFTSV (Figure 4B, Figure 4C) showed that these residues are essential for identifying specific primers. However, a structural comparison between RVFV and SFTSV L proteins demonstrated a distinct difference in their priming loops (Figure 4C). The RVFV  $L_{RNA}$  protein (green) priming loop is located next to the template exit tunnel and extrudes from the polymerase active center cavity to the surface of the protein, forming a compact interaction with the thumb domain and thumb ring domain (Figure 4D, Supplementary Figure S11). The priming loop of SFTSV L protein extends to the polymerase active center, so the template exit tunnel is smaller in the pre-initial state of replication (Figure 5B). The  $L_{RNA}$  protein thumb ring domain residues (Cys1419, Glu1435, Asp1436) are tightly bound with several priming loop residues (Thr1334, Ile1335, Glu1337), and the thumb domain residues (Glu1216, Thr1217, Gly1279, Phe1315) act on the other part of the priming loop residues (Trp1328, Leu1349, Ser1350, Ser1352, Leu1353) (Figure 4D). These two domains strictly regulate the conformation of the priming loop to adapt to different stages of viral replication or transcription (Figure 4D). The tight cooperation of these two domains provides a larger space for template exiting (Figure 5A). We speculate that the  $L_{RNA}$  protein is in the elongation compatible state, consistent with LACV and FluA polymerase structures<sup>26,37</sup> (Figure 5C, D).

315




316

317 **Figure 5. The entrance and exit channels of Rift Valley fever virus (RVFV), SFTSV, LACV  
318 and FluA polymerases**319 The template entry, NTP entry, template exit, and product exit channels of (A) RVFV L<sub>RNA</sub>  
320 protein, (B) SFTSV L<sub>apo</sub> protein (PDB 6L42), (C) LACV L protein (PDB 6Z8K), (D) Influenza A  
321 polymerase (FluA) (PDB 6T0V) are colored in limegreen, yelloworange, salmon, and magenta,  
322 respectively. The colors of the RVFV L domains are the same as those used in Figure 2A.  
323324 **Comparison of four channels**

325

326 The catalytic residues of the polymerases are at the center of an enclosed cavity connected to  
327 the exterior by four channels: an incorporated template entry channel, template exit channel, NTP  
328 entry channel, and product exit channel (Figure 5). The configurations of the four tunnels of  
329 RVFV L protein are similar to those described for SFTSV and LACV L proteins, and for Flu A  
330 polymerase (Figure 5). The template entry channel is mainly composed of vRBL, core lobe, and  
331 thumb domains. The conserved Trp513 aromatic residue, located on an  $\alpha$ -helix of the vRBL  
332 domain adjacent to the core lobe domain, is critical for stabilizing the vRBL domain and core lobe

domain by interacting with Phe581, Pro328, Val517, Leu654, and Leu658. Residues Ser1411, Leu1412, and Ser1413 (bridge domain), located in the middle of the template entry channel, are involved in identifying the sequence-specific template entry process. Similar to that in SFTSV polymerase, the  $\alpha$ -ribbon in RVFV polymerase is distant from the template entry channel. The NTP entry channel is mainly composed of the core lobe domain and fingers domain, and the fingers domain separates the NTP entry and template entry channels (Figure 5A). The product exit channel is surrounded by endonuclease, linker, fingers, thumb, and bridge domains. The bridge domain blocks the product exit channel from the template exit channel (Figure 5A). When RNA is added, the template exit and template entry channels become relatively spacious (Supplementary Figure S11). The domains around the template exit channel undergo conformational change triggered by vRNA and expand outward. Although the vRNA is not resolved in the L<sub>RNA</sub> structure, the binding of vRNA affects protein conformation and keeps the RVFV L protein in a state of replication elongation. In contrast, the SFTSV L<sub>apo</sub> template exit tunnel is narrower compared than our L<sub>RNA</sub> structure (Figure 5B).



**Figure 6. Superposition of low-resolution *ab initio* model and rigid body model**  
 (A) The *ab initio* model is shown as light-gray spheres. PA-like, PB1-like, and PB2-like N-terminal domains of RVFV L protein are colored in green. The simulated PB2 C-terminal domain is colored in yellow.  
 (B) Comparison of SAXS experimental data and calculated scattering profiles. Experimental data are represented in black dots. The data calculated from the RVFV L protein is in red.

## DISCUSSION

According to the World Health Organization, RVF is one of the top 20 global pandemic and epidemic diseases (<https://www.who.int/emergencies/diseases/en/>). In the 21st century, multiple RVF outbreaks have occurred, causing devastating effects on global health and economics. The RVFV polymerase, is located on the ‘L’ segment of the genome, and is the largest protein in the virus, with a molecular mass of approximately 238 kDa. Moreover, no RNA-dependent RNA polymerase structures of the genus *Phlebovirus* have been reported. Here, after optimizing the expression and purification of this large protein, we solved the first L protein structures of the genus *Phlebovirus* in the presence and absence of vRNA. Comparison of the RdRp core structure with those previously reported in *Bunyavirales* (SFTSV) and other two sNSRV families, including *Arenaviridae* (lassa virus and machupo virus) and Orthomyxoviridae (influenza) (Supplementary Figure S13), revealed that the RdRp core is typically conserved (Supplementary Figure S13B).

368 The N-terminal endonuclease domain connects to the polymerase core via a flexible linker  
369 ([Supplementary Figure S13A](#)). By contrast, the C-terminal domain is tightly integrated into the  
370 thumb subdomain of the polymerase core. All domains contribute to the formation of the channels  
371 that facilitate template entry and exit, NTP entry, and product exit ([Figure 5](#)). Our results reveal  
372 that the RVFV polymerase has compact core structure and is a flexible multidomain protein.  
373 Comparison of the L<sub>apo</sub> and L<sub>RNA</sub> proteins indicates that considerable conformational changes are  
374 induced upon RNA interaction ([Supplementary Figure S11](#), [Movie S1](#)).

375

376 The segmented single strand RNA genomes of negative-sense viruses perform two distinct  
377 RNA synthetic processes: genome replication via producing a positive-sense antigenome that acts  
378 as a template to generate progeny negative-strand genomes, and transcription including capped,  
379 and polyadenylated subgenomic messenger RNAs. As in other negative-sense viruses, the vRNA  
380 in RVFV is packaged with two virally expressed proteins (N and L protein), into a  
381 ribonucleoprotein (RNP) complex that is competent for replication and transcription. RNP  
382 complexes are generally formed by nucleoprotein winding of genomic RNA to form a rope, and  
383 both termini of each N-encapsidated genomic RNA segment can bind to one copy of the viral L  
384 polymerase protein. Unlike other negative-strand RNA viruses, the RVFV RNP complex has no  
385 helical symmetry. The nucleoprotein-encapsulated RNA is shaped like a flexible rope <sup>38</sup>.

386

387 RVFV replication and transcription occur in the cytoplasm. This is unlike the influenza virus,  
388 which vRNPs are transported into the nucleus for replication and transcription <sup>39</sup>. Replication is a  
389 primer-independent process. First, a replication intermediate called cRNA (complementary RNA)  
390 is synthesized, and then cRNA is used as a template for replication. In the pre-initial stage of  
391 replication, the priming loop is disordered ([Supplementary Figure S11A](#)). The priming loop  
392 undergoes large movements with the addition of template RNA ([Supplementary Figure S11B](#)), and  
393 is distinctly different from those of other L proteins of bunyaviruses ([Figure 4C](#)). Then, the  
394 priming loop recruits the first nucleotide to bind to the vRNA, and provides sufficient space in the  
395 active center for the replication product <sup>26</sup>. Consistent with the replication initiation mechanism in  
396 SFTSV <sup>21</sup>, called prime and realign, initiation of replication in RVFV might occur at several  
397 positions in the 3' vRNA template.

398

399 Our *in vitro* experiments showed that the replication product was not detected when using the 5'  
400 and 3' ends of any of or all of the three viral genome segments as transcription templates. The low  
401 activity is guessed that the synthesized templates (20 nt) are short, the last nucleotide A (is  
402 complementary to the detected fluorescein-12-UTP) in the template is far away from the 3' end  
403 and the detection method is not very sensitive. Moreover, N or other cofactors might be required  
404 to form a complex such as RNP to increase polymerase activity. Therefore, we redesigned the  
405 template RNA with an A at the 3' end, and with a U as the first base of the synthesized product at  
406 the 5' end. This increased the amount of the fluorescent product, making it easier to detect.  
407 Surprisingly, when only one template RNA was added, the L protein was capable of replication  
408 ([Figure 1D](#)). Therefore, the RVFV L protein can incorporate a nucleotide into a  
409 nucleotide/oligonucleotide in the absence of 5' vRNA, and this activity is notably enhanced by the  
410 addition of the 5' vRNA. This is different from the replication mode of most bunyaviruses that  
411 require both 5' vRNA and 3' vRNA for successful replication. Interestingly, 5' vRNA can

412 significantly increase the RNA polymerase activity. This is because the basic residues (Lys918 and  
413 Arg926) in the fingertips domain ([Figure 3D, 3E, Supplementary Figure S10E](#)) might bind the 5'  
414 viral RNA and stabilize the RdRp core structure.

415

416 Transcription of RVFV genomes is a primer-dependent process that involves capturing host  
417 capped RNAs using a cap-snatching mechanism. During cap-snatching, short capped fragments  
418 are snatched by cap-binding domain (CBD) and host mRNAs are cleaved at a position close to the  
419 5' cap by the polymerase endonuclease domain. Although we successfully obtained the full-length  
420 protein, we were unable to fit the C-terminal CBD into the cryo-EM density in both structures.  
421 The CBD might need capped vRNA to stabilize the conformation. To understand the location of  
422 the CBD is in the RVFV L protein structure, we used the pure, monodisperse, and monomeric  
423 full-length RVFV L protein to perform SAXS experiments and obtained a low-resolution structure  
424 in solution ([Figure 6](#)). Using the rigid body fitting of the recently published PB2 C-terminal  
425 including CBD<sup>24</sup>, the L<sub>RNA</sub> protein structure, and the endonuclease domain of RVFV L<sub>apo</sub> protein,  
426 we obtained an integrated RVFV L protein model ([Figure 6A](#)), which fit well with the SAXS  
427 envelope ([Figure 6B](#)). The integrated RVFV L protein model shows that the endonuclease and  
428 CBD domains are close to each other, which is supported by their functions: the CBD captures  
429 RNA and passes it to the endonuclease domain for cutting to be used as transcription primer.

430

431 At present, viral RdRps are promising drug targets. For example, Ribavirin, a broad-spectrum  
432 antiviral drug that selectively inhibits the RNA-dependent RNA polymerase, is active against  
433 hemorrhagic fever viruses in cell culture systems. Ribavirin has both prophylactic and therapeutic  
434 efficacy against bunyavirus, especially on genus *Phlebovirus*. Within 24 hours after infection, the  
435 combined treatment with favipiravir and ribavirin significantly increases survival outcomes and  
436 reduces virus titers in serum and tissue<sup>40</sup>. Using liposomes as drug carriers, a nontoxic, low-dose  
437 regimen of ribavirin had a therapeutic effect comparable to that achieved with higher, but  
438 potentially more toxic, doses of free ribavirin<sup>41</sup>. Mitoxantrone also alleviates severe diseases  
439 caused by RVFV in mice<sup>42</sup>. Moreover, the inhibitory effect of 2'-Fluoro-2'-deoxycytidine on RVF  
440 is over ten-times stronger than that of ribavirin<sup>43</sup>. Thus, our structures provide an important basis  
441 for developing effective antivirals for protecting humans and animals exposed to, and infected  
442 with, RVFV.

443

444

445 **MATERIALS AND METHODS**

446

447 **Small scale expression**

448 The codon-optimized sequence for RVFV (strain: ZH-501, GenBank: DQ375406.1) L protein was  
449 synthesized and cloned (using the seamless assembly cloning method) into a modified pPICZ  
450 expression vector with a C-terminal 6 × His tag without/with a GFP tag (*EcoR I/Nco I*) under the  
451 AOX1 promoter. Each single colony was inoculated into 5 mL of YPD medium (1% yeast extract,  
452 2% peptone, 2% glycerol) in a 50-mL centrifuge tube and incubated at 30°C in a shaking  
453 incubator (170 rpm) until the culture reached an OD<sub>600</sub> = 6 (approximately 24 hours). The cells  
454 were harvested by centrifugation at 3,000 × g for 2 minutes at 4°C. The supernatant was decanted,  
455 and the cell pellets were resuspended in approximately 5 mL of BMM medium (100 mM  
456 potassium phosphate, pH 6.0, 1.34% YNB, 1% methanol) to induce expression. Methanol was  
457 added to a final concentration of 1% every 24 hours to maintain induction. Cell pellets were  
458 analyzed for protein expression by western blot or GFP fluorescence detection. The extremely low  
459 level of wild-type L protein expression makes it impossible to obtain the protein by purification.  
460 To improve protein expression, we tried expressing several different mutants which were located  
461 away from the endonuclease active center. We found that expression of the D103A mutant protein  
462 was significantly increased, so this site was mutated in all of our proteins. In the manuscript, this  
463 protein is referred to as wild type because the mutant has endonuclease activity ([Supplementary](#)  
464 [Figure S1](#)).

465

466 **Protein expression and purification**

467 His tagged L protein was expressed in the X-33 *Pichia* strain in BMM medium at 28°C for 48  
468 hours after induction with 1% methanol. After pelleting, cells were resuspended in 50 mM  
469 Tris-HCl pH 8.5, 1 M NaCl, 5% glycerol, 20 mM imidazole and 5 mM benzamidine  
470 hydrochloride. The cells were lysed in the presence of 1 mM protease inhibitor (phenylmethyl  
471 sulfonyl fluoride (Invitrogen)) using a high pressure cell disruption system and the crude lysate  
472 was centrifuged at 47,000 × g for 50 minutes at 4°C to isolate the supernatant. The protein was  
473 purified from the soluble fraction by Ni affinity chromatography (GenScript), and was washed  
474 using a buffer containing 20 mM imidazole, 50 mM Tris-HCl pH 8.5, 1 M NaCl, 5% glycerol, and  
475 5 mM benzamidine hydrochloride to eliminate non-specific proteins. The elution buffer contained  
476 50 mM imidazole. The eluted protein was concentrated using an Amicon Ultra centrifugal filter  
477 (Millipore). The protein was further purified by size exclusion chromatography using a Superdex  
478 200 10/300 GL (GE Healthcare) column equilibrated in 20 mM BTP (1,3-Bis [tris (hydroxymethyl)  
479 methylamino] propane) pH 8.5, 300 mM NaCl, and 2 mM β-ME. Collected protein fractions were  
480 concentrated to 2 mg/mL and stored at 4°C for further use.

481 The protein tagged only with His uses a 6×His tag as the basis of *Pichia* protein expression  
482 screening. However, this method is cumbersome, the detection is not sensitive, and it requires  
483 considerable time to screen the strains expressing the protein. We improved the expression  
484 screening using a GFP-6×His Tag. The GFP fluorescence screening method was more convenient,  
485 simple to operate, and highly sensitive. GFP-positive cells were resuspended in 50 mM Tris-HCl  
486 pH 8.5, 500 mM NaCl, 5% glycerol, 20 mM imidazole, and 5 mM benzamidine hydrochloride.  
487 The lysate was centrifuged at 47,000 × g for 50 minutes to remove cell debris and was loaded onto  
488 Ni affinity chromatography (GenScript). The elution buffer was the same as the washing buffer

489 (20 mM imidazole, 50 mM Tris-HCl, pH 8.5, 500 mM NaCl, 5% glycerol, and 5 mM benzamidine  
490 hydrochloride) but contained an additional 50 mM imidazole. After changing the buffer to remove  
491 the imidazole, the GFP-6×His Tags were removed by the tobacco etch virus protease at a 1:1 (w/w,  
492 protease/protein) ratio at 4°C overnight. Then, the mixture was purified using Ni affinity  
493 chromatography (GenScript). Fractions containing L protein were collected and applied to a  
494 Superdex 200 10/300 GL (GE Healthcare) column equilibrated in 50 mM Tris-HCl pH 8.5, 500  
495 mM NaCl, and 5% glycerol. The fractions were flash-frozen, and stored at -80°C. All protein  
496 purification procedures were performed at 4 °C.

497

#### 498 **Endonuclease activity assay**

499 The FAM-5'-Poly-A RNA 30 mer was chemically synthesized (Sangon Biotech). Reactions  
500 containing 0.06 µM protein and 0.45 µM FAM-5'-Poly-A RNA were performed in a volume of 20  
501 µl with 0.5 U/µl RNasin (Promega), 100 mM HEPES pH 7.0, 100 mM NaCl, 5 mM dithiothreitol  
502 (DTT), and divalent cations as indicated in the figure legends, and incubated at 30°C for 40  
503 minutes. The reaction was stopped by adding an equivalent volume of RNA loading buffer (95%  
504 formamide, 0.5 mM EDTA, 0.025% SDS, and 0.025% xylene cyanol) and heating the samples at  
505 100°C for 3 minutes. Products were separated by electrophoresis on denaturing 7 M urea, 20%  
506 polyacrylamide Tris-borate-EDTA gels. Fluorescence was visualized using a ChemiDoc MP  
507 (BIO-RAD).

508

#### 509 **Polymerase activity assay**

510 For the *de novo* initiation of replication, 0.37 µM RVFV polymerase was mixed with 1 µM 20 nt 5'  
511 end of the RVFV M genome segment (5' M: 5'-ACACAAAGACGGUGCAUUAA-3') or/and 1  
512 µM 20 nt template RNA (5'-UGUGUUUCUGGCCACGU-3'), NTPs (25 µM ATP, 25 µM  
513 GTP, 25 µM CTP and 16.25 µM UTP) and 8.75 µM fluorescein-12-UTP (Sigma) in assay buffer  
514 (50 mM Tris-HCl pH7.0, 12 mM DTT, 0.25 mM MnCl<sub>2</sub>, 4 mM MgCl<sub>2</sub>). Reactions were incubated  
515 at 30°C for 3 hours and samples were analysed on a 20% acrylamide, 7 M urea denaturing gels.  
516 The fluorescence was visualized in a ChemiDoc MP (BIO-RAD).

517

#### 518 **Cryo-EM sample preparation and data collection**

519 The two vRNA oligonucleotides (5' vRNA 5'-GGUGCA-3' and 3' vRNA  
520 3'-UGUGUUUCUGGCCACGU-5') were annealed by heating at 95 °C for 5 min followed by  
521 cooling down on bench at room temperature to form partially double-stranded RNA. These two  
522 oligonucleotides are conserved 3' and 5' vRNA ends of viral genome and the selection is similar to  
523 that described for La Crosse encephalitis virus (LACV)<sup>25,26</sup>. This partially dsRNA was then mixed  
524 with L protein in a 1.1:1 molar ratio at 4 °C for 3 hours and the complex L<sub>vRNA</sub> was ultimately  
525 resolved on Superdex 200 10/300 GL in a gel filtration buffer (50 mM BTP pH 8.5, 300 mM  
526 NaCl). Aliquots of 4 µL purified RVFV L<sub>vRNA</sub> protein at a concentration of ~0.4 mg/ml were  
527 applied to glow-discharged holey carbon Cu grids (Quantifoil R1.2/1.3) and 4 µL purified RVFV  
528 L<sub>apo</sub> protein at a concentration of ~0.264 mg/ml were applied to glow-discharged homemade  
529 graphene grids<sup>44</sup>. Then these two kinds of grids were flash-cooled in liquid ethane using an FEI  
530 Vitrobot Mark IV. After initial screening, the well-prepared cryo-specimens were transferred onto  
531 an FEI Titan Krios transmission electron microscope operated at 300 kV for data collection. The  
532 microscope was equipped with a GIF-Quantum energy filter, which was used with a slit width of

533 20 eV. Images were recorded using a K3 Summit direct electron counting camera (Gatan Inc.) at a  
534 calibrated magnification of 64,000 (pixel size of 1.08 Å). The defocus range of the datasets was  
535 roughly -1.0 to -3.0 μm.

536

### 537 **Image processing**

538 Beam induced motion and anisotropic magnification were corrected using the MotionCor2  
539 program<sup>45</sup>. The initial contrast transfer function (CTF) parameters were estimated by the Gctf  
540 program<sup>46</sup> at the micrograph level and the micrographs with the estimated resolution limit worse  
541 than 5 Å were discarded. The selected Gctf star file was imported into RELION 3.0.8 program<sup>47</sup>  
542 and all subsequent particle picking, classification, and reconstruction progress were performed in  
543 RELION 3.0.8.

544 For the RVFV L<sub>RNA</sub> protein dataset, about 5,090,000 particles were automatically selected from  
545 about 3,700 micrographs. After two rounds of extensive 2D classification, a subset of 3,380,000  
546 particles were selected and further subjected to 3D classification with an initial model that was  
547 produced by the RELION program and low-pass filtered to a resolution of 40 Å. Because of the  
548 large amount of particles, we chose to split the particles into 3 groups and did the 3D classification  
549 separately. We used the same procedure of 3D classification on all the 3 groups separately. During  
550 the 3D classification, we used an angular sampling interval of 7.5 degree and did not perform local  
551 angular search. After all the three groups were executed with primary 3D classification, we joined  
552 the particles into a total dataset of 1,184,890 particles to do further 3D classification. After two  
553 rounds of 3D classification, a reconstruction from 554,102 particles displayed clear features of  
554 secondary structural elements. We then performed 3D refinement from the ~550,000 particles,  
555 yielding a reconstruction at a resolution of 3.84 Å. After postprocessing, we got a final map at 3.6  
556 Å resolution as determined by the Fourier shell correlation (FSC) 0.143 cut-off value.

557 For the RVFV L<sub>apo</sub> protein, we totally had three datasets. For each dataset, we did primary 2D  
558 classification and first round of 3D classification as the L<sub>RNA</sub> dataset by the RELION program.  
559 What is different from the L<sub>RNA</sub> dataset is that we could find out the endonuclease domain density  
560 in the second round of 3D classification although the number of these particles that contain  
561 endonuclease domain density is small. From the three datasets, we finally got 303,964  
562 endonuclease domain density containing particles together to perform 3D refinement, yielding a  
563 reconstruction at a resolution of 4.01 Å. After postprocessing, we got a final map at 3.84 Å  
564 resolution as determined by the Fourier shell correlation (FSC) 0.143 cut-off value.

565

### 566 **Model building**

567 The SFTSV L structure was used to guide manual building of RVFV L<sub>RNA</sub> by Chainsaw<sup>48</sup>. Manual  
568 model building was carried out using Coot<sup>49</sup> and refinement of the coordinates was performed  
569 using Phenix<sup>50</sup>. The structure of apo is a structural analysis based on RNA-bound L as a model.

570

### 571 **Small-angle X-ray scattering**

572 The overall model of the full-length RVFV L protein was obtained with the solved RVFV Lapo  
573 (without the Lariat) and the simulated PB2 C-terminal domain built from the structure of SFTSV  
574 (PDB 6L42) using the SASREF<sup>51</sup> with the distance restriction between the linker domain and the  
575 Lariat.

576 Small-angle X-ray scattering measurements were performed on beamline BL19U2 at the SSRF  
577 following previously published methods <sup>52</sup>. Briefly, all proteins were subjected to size exclusion  
578 chromatography in a buffer containing 20 mM BTP pH 8.5, 300 mM NaCl. The BioXTAS RAW  
579 software was used for data processing. GNOM provided the pair distribution function P(r) of the  
580 particle, the maximum size D<sub>max</sub> and the Porod volume. The 20 individual ab initio reconstructions  
581 were generated with DAMMIN, averaged using DAMAVER, and aligned using SUPCOMB. The  
582 structures were visualized using PyMOL.

583  
584

585     **Data availability**

586         Structural data are available from the PDB database (<http://www.rcsb.org/pdb/home/home.do>)  
587         (accession numbers 7EEI and 7EFE). EM data have been deposited with the EMDB (accession  
588         number EMD-31077 and EMD-31085). All remaining relevant data are included in the manuscript  
589         and its supplementary material.

590     **Acknowledgments:**

591         We thank J.L. Lei, Y.J. Xu and T. Yang for their support in cryo-EM and high-performance  
592         computation in the National Protein Science Facility (Beijing) at Tsinghua University. We thank J.  
593         Wen and X.M. Li for their friendly help in cryo-EM sample screening in the National Protein  
594         Science Facility (Beijing) at Tsinghua University. We thank Y. Li, C. Liu for some cryo-EM  
595         dataset collection at Shuimu Inc. Beijing. We would like to thank the staff of beamlines BL19U2  
596         at the Shanghai Synchrotron Radiation Facility for the excellent technical assistance.

597     **Funding**

598         This work was supported financially by National Key Research and Development Program of  
599         China [2018YFE0113100, 2016YFA0501100 to H.-W.W.]; National Natural Science Foundation  
600         of China [31825009 to H.-W.W. and 31872713, 32071210, and 31800629], Open Fund of the  
601         State Key Laboratory of Pathogenic Microbial Biosafety [SKLPBS1834].

602     **Declaration of Competing Interest**

603         The authors declare no conflict of interest.

604

605     **Author Contributions**

606         Conceptualization, Z.C. and H.W.; methodology, Z.C. and H.W.; software, X.W., C.H., Z.C. and  
607         H.W.; formal analysis, W.Y., J.W., X.D., J.X., X.L., M.Z., H.L., W.W. and F.Z.; investigation,  
608         X.W., C.H., Z.C. and H.W.; resources, Z.C. and H.W.; data curation, X.W., C.H., Z.C. and H.W.;  
609         writing—original draft preparation, X.W., C.H., Z.C. and H.W.; writing—review and editing,  
610         X.W., C.H., Z.C. and H.W.; supervision, Z.C. and H.W.; project administration, Z.C. and H.W.;  
611         funding acquisition, Z.C., H.W.

612

613      **References:**

- 614
- 615      1. Freiberg, A.N., Sherman, M.B., Morais, M.C., Holbrook, M.R. & Watowich, S.J.  
616      Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron  
617      tomography. *J. Virol.* **82**, 10341-8 (2008).
- 618      2. Komoda, K., Narita, M., Yamashita, K., Tanaka, I. & Yao, M. Asymmetric Trimeric Ring  
619      Structure of the Nucleocapsid Protein of Tospovirus. *J. Virol.* **91**, e01002-17 (2017).
- 620      3. Reguera, J. et al. Comparative Structural and Functional Analysis of Bunyavirus and  
621      Arenavirus Cap-Snatching Endonucleases. *PLoS Pathog* **12**, e1005636 (2016).
- 622      4. Eifan, S., Schnettler, E., Dietrich, I., Kohl, A. & Blomstrom, A.L. Non-structural proteins of  
623      arthropod-borne bunyaviruses: roles and functions. *Viruses* **5**, 2447-68 (2013).
- 624      5. Salekwa, L.P., Wambura, P.N., Matiko, M.K. & Watts, D.M. Circulation of Rift Valley Fever  
625      Virus Antibody in Cattle during Inter-Epizootic/Epidemic Periods in Selected Regions of  
626      Tanzania. *Am. J. Trop. Med. Hyg.* **101**, 459-466 (2019).
- 627      6. Flick, R., et al. Rift Valley fever virus. *Curr Mol Med* **5**, 827-34 (2005).
- 628      7. Guardado-Calvo, P. et al. A glycerophospholipid-specific pocket in the RVFV class II  
629      fusion protein drives target membrane insertion. *Science* **358**, 663-667 (2017).
- 630      8. Golnar, A.J., Turell, M.J., LaBeaud, A.D., Kading, R.C. & Hamer, G.L. Predicting the  
631      mosquito species and vertebrate species involved in the theoretical transmission of Rift  
632      Valley fever virus in the United States. *PLoS Negl Trop Dis* **8**, e3163 (2014).
- 633      9. Vloet, R.P.M. et al. Transmission of Rift Valley fever virus from European-breed lambs to  
634      Culex pipiens mosquitoes. *PLoS Negl Trop Dis* **11**, e0006145 (2017).
- 635      10. Nielsen, S.S. et al. Rift Valley Fever - epidemiological update and risk of introduction into  
636      Europe. *EFSA J.* **18**, e06041 (2020).
- 637      11. Wang, Q. et al. Neutralization mechanism of human monoclonal antibodies against Rift  
638      Valley fever virus. *Nat Microbiol* **4**, 1231-1241 (2019).
- 639      12. Balenghien, T. et al. Towards a better understanding of Rift Valley fever epidemiology in  
640      the south-west of the Indian Ocean. *Vet. Res.* **44**, 78 (2013).
- 641      13. Lokugamage, N., Freiberg, A.N., Morrill, J.C. & Ikegami, T. Genetic subpopulations of Rift  
642      Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains. *J. Virol.* **86**,  
643      13566-75 (2012).
- 644      14. Gogovi, G.K. et al. Modeling the Tertiary Structure of the Rift Valley Fever Virus L Protein.  
645      *Molecules* **24**, 1768(2019).
- 646      15. Balkhy, H.H., et al. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. *Int J*  
647      *Antimicrob Agents* **21**, 153-7 (2003).
- 648      16. Terasaki, K., Murakami, S., Lokugamage, K.G. & Makino, S. Mechanism of tripartite RNA  
649      genome packaging in Rift Valley fever virus. *Proc Natl Acad Sci U S A* **108**, 804-9 (2011).
- 650      17. Pflug, A., Guilligay, D., Reich, S. & Cusack, S. Structure of influenza A polymerase bound  
651      to the viral RNA promoter. *Nature* **516**, 355-60 (2014).
- 652      18. Reich, S. et al. Structural insight into cap-snatching and RNA synthesis by influenza  
653      polymerase. *Nature* **516**, 361-6 (2014).
- 654      19. Gogrefe, N., Reindl, S., Gunther, S. & Rosenthal, M. Structure of a functional cap-binding  
655      domain in Rift Valley fever virus L protein. *PLoS Pathog* **15**, e1007829 (2019).
- 656      20. Ferron, F. et al. The hexamer structure of Rift Valley fever virus nucleoprotein suggests a

- 657 mechanism for its assembly into ribonucleoprotein complexes. *PLoS Pathog* **7**, e1002030  
658 (2011).
- 659 21. Vogel, D. et al. Structural and functional characterization of the severe fever with  
660 thrombocytopenia syndrome virus L protein. *Nucleic Acids Res.* **48**, 5749-5765 (2020).
- 661 22. Kumar, G., Cuypers, M., Webby, R.R., Webb, T.R. & White, S.W. Structural insights into the  
662 substrate specificity of the endonuclease activity of the influenza virus cap-snatching  
663 mechanism. *Nucleic Acids Res.* **49**, 1609-1618 (2021).
- 664 23. Heinrich, B.S., Cureton, D.K., Rahmeh, A.A. & Whelan, S.P. Protein expression redirects  
665 vesicular stomatitis virus RNA synthesis to cytoplasmic inclusions. *PLoS Pathog* **6**,  
666 e1000958 (2010).
- 667 24. Wang, P. et al. Structure of severe fever with thrombocytopenia syndrome virus L protein  
668 elucidates the mechanisms of viral transcription initiation. *Nat Microbiol* **5**, 864-871  
669 (2020).
- 670 25. Gerlach, P., Malet, H., Cusack, S. & Reguera, J. Structural Insights into Bunyavirus  
671 Replication and Its Regulation by the vRNA Promoter. *Cell* **161**, 1267-79 (2015).
- 672 26. Arragain, B. et al. Pre-initiation and elongation structures of full-length La Crosse virus  
673 polymerase reveal functionally important conformational changes. *Nat. Commun.* **11**,  
674 3590 (2020).
- 675 27. Bouloy, M., et al. Molecular biology of rift valley Fever virus. *Open Virol J* **4**, 8-14 (2010).
- 676 28. te Velthuis, A.J. Common and unique features of viral RNA-dependent polymerases. *Cell*  
677 *Mol. Life Sci.* **71**, 4403-20 (2014).
- 678 29. Jacome, R., Becerra, A., Ponce de Leon, S. & Lazcano, A. Structural Analysis of Monomeric  
679 RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications. *PLoS ONE* **10**,  
680 e0139001 (2015).
- 681 30. Yang, X. et al. Motif D of viral RNA-dependent RNA polymerases determines efficiency  
682 and fidelity of nucleotide addition. *Structure* **20**, 1519-27 (2012).
- 683 31. Venkataraman, S., Prasad, B. & Selvarajan, R. RNA Dependent RNA Polymerases: Insights  
684 from Structure, Function and Evolution. *Viruses* **10**, 76 (2018).
- 685 32. Thierry, E. et al. Influenza Polymerase Can Adopt an Alternative Configuration Involving a  
686 Radical Repacking of PB2 Domains. *Mol Cell* **61**, 125-37 (2016).
- 687 33. Madeira, F. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic*  
688 *Acids Res.* **47**, W636-W641 (2019).
- 689 34. Te Velthuis, A.J., Robb, N.C., Kapanidis, A.N. & Fodor, E. The role of the priming loop in  
690 Influenza A virus RNA synthesis. *Nat Microbiol* **1**, 16029 (2016).
- 691 35. Bailey, T.L., et al. Fitting a mixture model by expectation maximization to discover motifs  
692 in biopolymers. *Proc Int Conf Intell Syst Mol Biol* **2**, 28-36 (1994).
- 693 36. Liang, B. et al. Structure of the L Protein of Vesicular Stomatitis Virus from Electron  
694 Cryomicroscopy. *Cell* **162**, 314-327 (2015).
- 695 37. Wandzik, J.M. et al. A Structure-Based Model for the Complete Transcription Cycle of  
696 Influenza Polymerase. *Cell* **181**, 877-893 (2020).
- 697 38. Raymond, D.D., Piper, M.E., Gerrard, S.R. & Smith, J.L. Structure of the Rift Valley fever  
698 virus nucleocapsid protein reveals another architecture for RNA encapsidation. *Proc Natl*  
699 *Acad Sci U S A* **107**, 11769-11774 (2010).
- 700 39. Te Velthuis, A.J. Influenza virus RNA polymerase: insights into the mechanisms of viral

- 701 RNA synthesis. *Nat Rev Microbiol* **14**, 479-93 (2016).
- 702 40. Scharton, D. et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus  
703 infection and reduces delayed-onset neurologic disease observed with ribavirin  
704 treatment. *Antiviral Res* **104**, 84-92 (2014).
- 705 41. Kende, M., Alving, C.R., Rill, W.L., Swartz, G.M., Jr. & Canonico, P.G. Enhanced efficacy of  
706 liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice.  
707 *Antimicrob Agents Chemother* **27**, 903-7 (1985).
- 708 42. Lang, Y. et al. Identification and evaluation of antivirals for Rift Valley fever virus. *Vet.*  
709 *Microbiol*. **230**, 110-116 (2019).
- 710 43. Smee, D.F., Jung, K.H., Westover, J. & Gowen, B.B. 2'-Fluoro-2'-deoxycytidine is a  
711 broad-spectrum inhibitor of bunyaviruses in vitro and in phleboviral disease mouse  
712 models. *Antiviral Res* **160**, 48-54 (2018).
- 713 44. Zheng, L. et al. Robust ultraclean atomically thin membranes for atomic-resolution  
714 electron microscopy. *Nat. Commun.* **11**, 541 (2020).
- 715 45. Zheng, S.Q. et al. MotionCor2: anisotropic correction of beam-induced motion for  
716 improved cryo-electron microscopy. *Nat Methods* **14**, 331-332 (2017).
- 717 46. Zhang, K. Gctf: Real-time CTF determination and correction. *J. Struct. Biol.* **193**, 1-12  
718 (2016).
- 719 47. Scheres, S.H. RELION: implementation of a Bayesian approach to cryo-EM structure  
720 determination. *J. Struct. Biol.* **180**, 519-30 (2012).
- 721 48. Stein, N. CHAINSAW: a program for mutating pdb files used as templates in molecular  
722 replacement. *J. Appl. Crystallogr.* **41**, 641-643 (2008).
- 723 49. Emsley, P., et al. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D*  
724 *Biol. Crystallogr.* **60**, 2126-32 (2004).
- 725 50. Afonine, P.V. et al. Towards automated crystallographic structure refinement with  
726 phenix.refine. *Acta Crystallogr. D Biol. Crystallogr.* **68**, 352-67 (2012).
- 727 51. Petoukhov, M.V. & Svergun, D.I. Global rigid body modeling of macromolecular  
728 complexes against small-angle scattering data. *Biophys. J.* **89**, 1237-50 (2005).
- 729 52. Gao, Y. et al. Human apo-SRP72 and SRP68/72 complex structures reveal the molecular  
730 basis of protein translocation. *J Mol Cell Biol* **9**, 220-230 (2017).

## Manuscript title: Structural insights into Rift Valley fever virus replication machinery

Xue Wang<sup>1,4</sup>, Cuixia Hu<sup>2,4</sup>, Wei Ye<sup>3</sup>, Jia Wang<sup>2</sup>, Xiaofei Dong<sup>1</sup>, Jie Xu<sup>2</sup>, Xiaorong Li<sup>1</sup>, Manfeng Zhang<sup>1</sup>, Hongyun Lu<sup>1</sup>, Fanglin Zhang<sup>3</sup>, Wei Wu<sup>1</sup>, Hong-Wei Wang<sup>2,\*</sup> and Zhongzhou Chen<sup>1,\*</sup>

<sup>1</sup> State Key Laboratory of Agrobiotechnology and Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Biological Sciences, China Agricultural University, Beijing, China, 100193

<sup>2</sup> Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China, 100084

<sup>3</sup> Department of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, China

<sup>4</sup> These authors contributed equally: Xue Wang, Cuixia Hu.

\* To whom correspondence should be addressed:

Zhongzhou Chen

E-mail: [chenzhongzhou@cau.edu.cn](mailto:chenzhongzhou@cau.edu.cn)


Hong-Wei Wang

E-mail: [hongweiwang@tsinghua.edu.cn](mailto:hongweiwang@tsinghua.edu.cn) (H.-W.W.)

22 **Supplementary data**

23 Supplementary Table S1. Cryo-EM data collection, refinement, and validation statistics.

	RVFV L <sub>RNA</sub>	RVFV L <sub>apo</sub>
<b>Data collection and processing</b>		
Magnification	64,000	64,000
Voltage (kV)	300	300
Electron exposure (e <sup>-</sup> /Å <sup>2</sup> )	50	50
Defocus range (μm)	-1.0 to -3.0	-1.0 to -3.0
Pixel size (Å)	1.08	1.08
Symmetry imposed	C1	C1
Final particle images (no.)	660K	303K
Map resolution (Å)	3.6	3.84
FSC threshold	0.143	0.143
Map resolution range (Å)	3.5-4.7	3.7-5.7
<b>Refinement</b>		
Initial model used (PDB code)	6l42	
Map sharpening <i>B</i> factor (Å <sup>2</sup> )	-180	-180
Model composition		
Non-hydrogen atoms	10249	10273
Protein residues	1401	1410
<i>B</i> factors (Å <sup>2</sup> )		
Protein	104.67	116.07
R.m.s deviation		
Bond lengths (Å)	0.009	0.009
Bond angles (°)	1.498	1.103
<b>Validation</b>		
MolProbity score	1.76	1.41
Clashscore	5.25	7.54
Poor rotamers (%)	0.42	0.32
Ramachandran plot		
Favored (%)	92.26	100.00
Allowed (%)	7.74	0.00
Disallowed (%)	0.00	0.00




24

25 **Figure S1. Endonuclease activity assay.**

26 (A) 0.06  $\mu$ M RVFV L protein was incubated at 30°C for 40 min with 0.45  $\mu$ M fluorescently  
27 labeled 30 nt PolyA RNA substrate. Reactions in the presence of RVFV L (D111A), EDTA, or  
28 DPBA were negative controls.

29 (B) 0.06  $\mu$ M RVFV L protein was incubated at 30°C for 40 min with 0.45  $\mu$ M fluorescently  
30 labeled 30 nt PolyA RNA substrate in the presence of 25 mM MnCl<sub>2</sub>, MgCl<sub>2</sub>, CaCl<sub>2</sub>, ZnSO<sub>4</sub>,  
31 CoCl<sub>2</sub>, FeCl<sub>3</sub>, NiCl<sub>2</sub>, or CuSO<sub>4</sub>. The reaction in the presence of EDTA was negative control.




32

33 **Figure S2. Cryo-EM reconstruction of RVFV L<sub>RNA</sub> protein**

34 (A) Raw image of RVFV L<sub>RNA</sub> protein particles in vitreous ice recorded by K3 camera at defocus  
 35 range of -1.5 to 2.5 μm. Scale bar 100 nm.

36 (B) Power spectrum of image (A) and the white circle indicated the spatial frequency  
 37 corresponding to 3.19 Å estimated by the Gctf program.


- 38 (C) Representative 2D classes. The box size of each class was 172.8 Å.  
39 (D) Fourier shell correlation (FSC) curves of the postprocessed 3D map, following the gold  
40 standard refinement.  
41 (E) Euler angle distribution.  
42 (F) Local resolution was performed with Relion3.1  
43 (G) The flowthrough of the data processing used to get the final map.  
44



45

46 **Figure S3. Cryo-EM reconstruction of RVFV L<sub>apo</sub> protein**

- 47 (A) Representative micrograph of RVFV L<sub>apo</sub> protein in vitreous ice after MotionCorr2 at defocus  
48 of ~1.6 μm, scale bar 100 nm.
- 49 (B) Power spectrum of the image shown in (A). White circle indicated the spatial frequency  
50 corresponding to 3.05 Å resolution.
- 51 (C) 2D classification result of the RVFV L<sub>apo</sub> protein.
- 52 (D) Fourier Shell Correlation (FSC) curves between the independently refined two half-maps  
53 showed the overall 3.84 Å resolution of the density map by the 0.143 cut-off.
- 54 (E) Angular distribution for particle projections visualized as a sphere around the RVFV L<sub>apo</sub> final  
55 density map.
- 56 (F) Local resolution estimation result, performed by Relion3.1.




57

58 **Figure S4. Cryo-EM data processing procedures of RVFV L<sub>apo</sub> protein.**


59 At the beginning of the data processing procedure, part1, we only collected about ~1,500  
60 micrographs to test whether this sample had the potential that could be reconstructed to a  
61 high-resolution map or not. It's delightful that we discovered the L protein's N-terminal density,  
62 indicated by the red arrow, in the second time of 3D classification. However, the number of  
63 protein particles that contain the endonuclease domain was not enough to reconstruct  
64 high-resolution map for modeling. Therefore, we collected more cryo-EM data of the same grid as  
65 part1, and the processing progress of next two data collections was shown in part2 and part3,  
66 respectively. Subsequently, we got 303,964 particles to do 3D auto-refinement and postprocessing

67 sharpening, which resulted in a map of 3.84 Å resolution calculated by the FSC curve with 0.143  
68 cutoff. In the end, we adopted this 3.84 Å resolution map for the model building.  
69  
70

A



B




71

72 **Figure S5. Directional FSC profile of (A)  $L_{RNA}$  and (B)  $L_{apo}$**

73 3DFSC plots of the final data were analyzed via the web portal for 3DFSC (<https://3dfsc.salk.edu>)

74 1.

75




76

77 **Figure S6. Representative cryo-EM map**


78 Representative regions of the protein model, colored as Figure 2A.

79

80

81 **Figure S7. RNAs were co-purified with RVFV L protein**


- 82 (A) Size-exclusion chromatogram (Superdex 200 10/300 GL) of RVFV L protein and RNA. The  
83 absorbance curves for the sample at wavelengths of 260 nm and 280 nm were given.
- 84 (B) RNA detection was performed on the collection corresponding to the SEC peak on the left by  
85 electrophoresis on 20% polyacrylamide gels containing 7 M urea. 3' vRNA stands for  
86 3'-UGGUUUCUGGCCACGU-5', 5' vRNA is 5'-GGUGCA-3'. Pro stands for before the  
87 column. + stands for individual RNA samples.
- 88 (C) Size-exclusion chromatogram (Superdex 200 10/300 GL) of RVFV L protein. The absorbance  
89 curves for the sample at wavelengths of 260 nm and 280 nm were given.
- 90



91

92 **Figure S8. Overall structure of the RVFV L<sub>apo</sub> protein.**


93 Overall dimension of this structure is about 95 Å x 70 Å x 108 Å. The dimension is larger than  
 94 that of RVFV L<sub>RNA</sub> protein due to the resolving of the endonuclease domain in L<sub>apo</sub> structure.



95

96 **Figure S9. Topology of RVFV L RNA protein.**


97 3<sub>10</sub> helices were colored gray. Linker domain was colored green, core lobe domain was colored  
 98 lightpink, vRBL domain was colored deeppurple, fingers domain was colored blue, palm domain  
 99 was colored red, thumb domain was colored darkseagreen, bridge domain was colored navyblue,  
 100 thumb ring domain was colored yellow.



101

102 **Figure S10. The structures for fingertips loops of apo MACV, apo LASV, apo FluC, LACV  
103 complex, RVFV L<sub>RNA</sub>, and RVFV L<sub>apo</sub> polymerase.**

104 The basic residues on the fingertips domain were marked. The side chain of K918 in RVFV L<sub>apo</sub>  
105 was flexible in the density.



106

107 **Figure S11. The entrance and exit channels comparison of RVFV L<sub>apo</sub> protein and RVFV**  
 108 **L<sub>RNA</sub> protein**

109 (A) RVFV L<sub>apo</sub> protein. Note that the priming loop is missing in the structure of L<sub>apo</sub>.


110 (B) RVFV L<sub>RNA</sub> protein.


	1	10	20	30	40	50	60	70
<b>RVFV</b>	.MDSI	L SKQL VDKTG	VRVP I KHF DCTMLTLA	L P TFDVS . KMVD RITID FNLDI QGASE	S E	G S	TLLPS . MSID	
<b>GTV</b>	MN LEV	L CGRINAEDGL	S LGEPGLFDQIYDRPGL	P DLDVS . VDATGVVVDIGAI . PDSA	S HLG S	SINAG . VINIQ		
<b>MUKV</b>	.MEPI	L SRI . GNFO G	FOKPQVQHHEADLFNTA	L PSFOVS . NTKAGLSLDVNLEDLDRE	STV GS	T ITKD . QVIP		
<b>TAV</b>	.MDVL	L EKQP KPTGKF	TKRAVVQYESFL LDNR	L INFEV L DSPEGGVTD FSIDDLDES	STV GS	TIPKV . KKVS		
<b>TOV</b>	.MNSI	I ERQEPLHDGF	TKRQLVHYNSTLMNAY	L PVYI VV . SDKDGVSIEVDRDNFDIG	S GTG KSI KDE . . RYG			
<b>KAMV</b>	.MLQA	I CSRTPLDGF	TCPPSRTYRSLQDRPSI	I PTFLVR . MDGSDICITFDLSDITSA	STG S	SLQPE . YKIT		
<b>SFTSV</b>	MN LEV	L CGRINVENGL	S LGEPGLDQIYDRPGL	P DLDVT . VDATGVTVDIGAV . PDSA	S QLGS	SINAG . LITIQ		
<b>UUKV</b>	.MLLA	I CSRTIRQQGL	NCPPAVTF TSSHMRPPI	P SFLLW . TEGSDVLMDFDLDTIPAG	S VTGS	SIGPK . F KIK		
<b>MUNV</b>	.MDEI	L INQPELKPGF	NNRALDNYHTDLMSIE	L PEFSLEKE . QNSLRIEISLSDLPS	S T I GS	TL RDNP GIIVE		
<b>LACV</b>				.MDYQEYQQFLARINTARDACVAKDID . . . . .				


	80	90	100	110	120	130
<b>RVFV</b>	VEDMANFV	D DFT F G I LADK TD . . . . .	RLLMREFP MMN D GFD H LSP D M I I KTT S G MY . . . . .	N I V E F T T F R G D		
<b>GTV</b>	LSEAYKIN	H DFT F S G LSKT TD . . . . .	RRL SE FP I A H D G S D G M T P D V I H T R L D G T I . . . . .	V V V E F T T T R S L		
<b>MUKV</b>	MDOI LN FV	H DFT F V A L LTKS TD . . . . .	S R F H N F F P L I G D G F D G H T P D D I I I T P G O R V . . . . .	F V V E Y T T N R G N		
<b>TAV</b>	P SGL KNF	H DFT F G Y A S S TD . . . . .	R R F H N F F M P L N D G F D S L S P D M I V R T P S G H H . . . . .	H V I E F A T F R G G		
<b>TOV</b>	F Q N L P N F V	H DFT F G Q L S A L T D . . . . .	V P F H S V F G K R R D G F D H L S P H A I F R T A A G S H . . . . .	F I V E F T T F R G G		
<b>KAMV</b>	K I E A S T F	H DFT F A L A P Q T D . . . . .	V R L K S V F P I T M G D T Y D G W T P D Y I C K R L D G S H . . . . .	N V V E F T T T N R S P		
<b>SFTSV</b>	LSEAYKIN	H DFT F S G LSKT TD . . . . .	R RL SE FP I T H D G S D G M T P D V I H T R L D G T I . . . . .	V V V E F S T T R S H		
<b>UUKV</b>	T Q A A S F V	H DFT F A H W C D A S D . . . . .	M P L R D H F P L V N D T F D H W T P D F I S Q R L D G S K . . . . .	V V V E F T T T N R S D		
<b>MUNV</b>	SEKL TN LV	H D I T V G I L A P N T D . . . . .	K M F S S V F P V K N D G F D G Y T P D M I I K T T A G A H . . . . .	Y I I E F T T F R G L		
<b>LACV</b>	.V D L L M A R	H D Y F G R E L C K S L N I E Y R N D V P F I D I I L D I R P E V D P L T I D A P H I T P D N Y L Y I N N V L Y I I D Y K V S V S N				


	140	150	160	170	180	190	200
<b>RVFV</b>	E R G A F . Q A M M T K L A K Y E	V P C E N R S Q . . . G R T V V L Y V V S A Y R H G V W S N L E L	E D S E A E E M V Y V R Y R L A L . . . S V M D E L				
<b>GTV</b>	N M G G L E A A Y R T K V E K Y R D P I S R R V D L M A R V F Y G I I V V S S S G V L T N M P L	T Q D E A E E L M Y R F C I A N . . . E I Y T K A					
<b>MUKV</b>	E R Q A E . Q A Y A T K F A K Y E	L A C Q N R S S . . . I M P I M L C V I S V H R D G V W S N L P L	T Q A E V D E L V F R F R L A V . . . A I F G E I				
<b>TAV</b>	D A G A E . S S A L S K I S K Y E	I A C S N R S E . . . Q F D I T L S V I T V Y K N G I I V H R D G V W S N L V L	E E D E V D E L V F R F R L A V . . . D V F E E L				
<b>TOV</b>	E G G C R . K A A Q N K L T K Y E	V A C E S R S S . . . N N R I G L F V I A V H R D G V W S N L V L	E E E V N E L V Y R F R L A V . . . A V F S V L				
<b>KAMV</b>	R E A A L F T A F N Q K V G K Y E	I P L K V R S Q . . . V S K I F F A V I A V G D D L I I S N L E L	N R A E V E E L C F R F I L A R . . . A V F A E L				
<b>SFTSV</b>	N I G G L E A A Y R T K I E K Y R D P I S R R V D I M E N P R V F F G	V I V V S S G G V L S N M P L	T Q D E A E E L M Y R F C I A N . . . E I Y T K A				
<b>UUKV</b>	Q E Q S L I S A F N T K V G K Y E	V A L H N R S T . . . T S S I L F G V V V V S E T T V V T N L N L	N Q Q E V D E L C F R F L V A R . . . A V H L E M				
<b>MUNV</b>	E A G A A . Q A M M S K L A K Y E	I P C I N R S S . . . E S T L S L C V I A V H R S G V V S N L I I L	K E D E V N E L V F R F R L A V . . . A I F Y E A				
<b>LACV</b>	E S S V I . . . T Y D K Y E L T R D I S D . . . R L S I P E I V I I R D P V S R D L H I N S D F K E L Y P T I V V D I N F N O F F D L						





	210	220	230	240	250
<b>RVFV</b>	R T L F P E L S S T D E E L . G K T E	E L L A M V S S I Q N I S V T E S . . . . .	V F P F S R E M F D R F R S S P . . . P D S		
<b>GTV</b>	R T M D A E V E L Q K T E E E L E A V S R A L S F F G L F D P N L Q K V E E . . . . .	T F P F N S D I R M L E E F L S S P . . . A D V			
<b>MUKV</b>	R E M S P D A L K D D P E E L . S K T E	E V L G I I S Q I P L D E K T S K . . . . .	A F F A F Q E S T I M G F L R S P . . . E D E		
<b>TAV</b>	E A K Y P D I T N I S E E M . S L T E G E	E V I G I V A D I K M D G K T E E . . . . .	O F F Y F K K E M F E S F K S R S . . . K D S		
<b>TOV</b>	K R R Y P E L S G D N D E L . T R A E S E	E L R G I V S S I K I D E R T Q E . . . . .	S F P S F K R D V I E S F K T F V . . . P N E		
<b>KAMV</b>	L D R A V I P E F E N P D E . D K H M R E	V R I A L S D I K F K E M T E E . . . . .	K F H P F I T R Q L Y E R Y Q N M T . . . P D T		
<b>SFTSV</b>	R S M D A D I E L Q K S E E E L E A I S R A L S F F S L F E P N I	E R V E G . . . . .	T F P P N S E I E M L E Q F L S T P . . . A D V		
<b>UUKV</b>	T T K M I I P E Y D D E D E . D K R S R E	E V K A A F H S V Q P D N V T E A . . . . .	N F A P F S R R M F S N F A Q M E . . . P D K		
<b>MUNV</b>	M K L C P E L T D D S E L . S K A E K E	I I G T I S M I S M D R R T E K . . . . .	S F P F F I R E D V H N F F M D T P . . . P D E		
<b>LACV</b>	K Q L L Y E K F G D D E F L L K V . . . A H G D F T . L T A P	E C T K T G C P E F W K H P I Y K E F K M S M P V	P E R R L F E E S V K F N A Y E S E		















	1690	1700	1710	1720	1730	1740	1750
<b>RVFV</b>	LQRFL .DGD ..HVVP IEE MGA	<b>GTV</b>	<b>G</b> GF IKR QQS .KVVQNKVV	<b>M</b> WGF MDG YQVHLEIENDIGQP .PRL			
<b>GTV</b>	I S NYFSQKG .GS IL DQIEKAQS	<b>G</b> TF GGF SKPORT FTRPGGS	<b>Y</b> YGVG WRG VMDG VQVQIDIDNREQEP .PQL				
<b>MUKV</b>	FQKFVSSSEQ ..SVI QDI I RVGA	<b>G</b> IV GGF TRP QRA .TKRDGKFH	<b>Y</b> HGP GTWRGVMDGVQVQIDIDNREQEP .PQL				
<b>TAV</b>	MQR YFLEEE ..DVPDLMYSINA	<b>G</b> IL GAF TYP QSA .KKIDGKV	<b>Y</b> HGS GS WRGVMDGVQVHIDIYNEVGET .AQI				
<b>TOV</b>	MQR YM QGD K .STLDI IEQVGA	<b>G</b> VV GGF VVR QRT .KL VQGKV	<b>Y</b> FG FG GV WRGVMDGVQIQVDVDNDLGQP .TNI				
<b>KAMV</b>	LQT FYGEH GKD V .FNSIEHANC	<b>G</b> V GGF SHROKS .RVEGDR	<b>I</b> YFG GDGV WRGL VDG FQVQITVFTPRNTTLTHV				
<b>SFTSV</b>	LSNYLSSKG .GS IL DQIERAQS	<b>G</b> TL GGF SKPOKTFIRPGGGVG	<b>Y</b> KGKGV WTDGVQVQIDIDNREQEP .PQL				
<b>UUKV</b>	FQDYFSKRGPD I IFNRIQMANC	<b>G</b> VI GGF TSP QPK .KEVDGKIV	<b>Y</b> TGDGV WRGVMDGVQIQQLVITYMPKQKSNEL				
<b>MUNV</b>	MQR FINGD .NLIREMEL IGA	<b>G</b> TV GGF TVR QKSSMGSDGK	<b>I</b> CYYGP GS WRGVMDGHQIQIDINNNQGLP .PHI				
<b>LACV</b>	LFR TGDL .	<b>R</b> OAD .LDKYDAMSKHERVT	<b>W</b> NDWOTSRHLDMG SIN LTIT .GYN				

	1760	1770	1780	1790	1800	1810
<b>RVFV</b>	RNVTTN .CQSSPWDL SIPI RQ	<b>M</b> AEDM GV T	<b>N</b> QDYSSKS .SRGARYWMHS	<b>F</b> RMQGPSK .		<b>P</b> F G
<b>GTV</b>	EEI RL S .SEARLYDVIESI RRL CDDLG	<b>I</b> IN RVASSF .R	<b>R</b> GHCMVRLSGF	<b>K</b> IKPASR .		<b>T</b> D G
<b>MUKV</b>	VAVT VS .GTQTPWAI I PSL OS	<b>W</b> CSOM GVL N	<b>S</b> CDVRSKS .R	<b>R</b> PGAKFWI YGF	<b>R</b> MSGPS	<b>P</b> Y G
<b>TAV</b>	RSIK VY .GTRSPWEI CQNIRS	<b>W</b> CD OVGAR N	<b>D</b> YDASRQKV .KSNADFWMFG	<b>F</b> KMSGAGH .		<b>PL</b> G
<b>TOV</b>	VAVH I VRSN VGPWELMRTL KA	<b>W</b> ADD M	<b>I</b> RN YDDVS RGS .RKGASYWMHQ	<b>F</b> KLT ASN L .		<b>T</b> F G
<b>KAMV</b>	KSI ELL .DEKAIR TL SI FLRN	<b>W</b> CD EMEV Y	<b>N</b> KADTSDFL .R	<b>T</b> TTGNFYVYDF	<b>N</b> IASSKN .	<b>K</b> F G
<b>SFTSV</b>	EEI RL S .SDARLYDVIESI RRL CDDLG	<b>I</b> IN RVASAY .R	<b>R</b> GHCMVRLSGF	<b>K</b> IKPASR .		<b>T</b> D G
<b>UUKV</b>	KSI TVN .SDRCISALSSFCQS	<b>W</b> CKEMG V	<b>F</b> N TEDFSKTQ .RFSKAS FMHFK	<b>I</b> KISGSQ .		<b>T</b> L G
<b>MUNV</b>	TSV SIS .DKVSPWDL CQS IKA	<b>W</b> AE DMO V	<b>K</b> NL TD IST TH .KRWLCKFW MYD	<b>F</b> KMFGSDK .		<b>P</b> F G
<b>LACV</b>	RSI TII .	<b>Q</b> EDN	<b>K</b> LTYAELCLTRKTPENIT	<b>S</b> GRKLLGSRHGLK FENMSK I QTY G		

	1820	1830	1840	1850	1860	1870
<b>RVFV</b>	<b>P</b> VYI IKG DMSD .	<b>V</b> IRLRKEE VEM KV	<b>R</b> GSTL	<b>N</b> LYTKHH .	<b>S</b> HQDLH	<b>I</b> LSY
<b>GTV</b>	<b>P</b> IRVLERGF WI .	<b>R</b> E LQNP DEV FMR V	<b>R</b> GD I	<b>N</b> L SVRI Q .	<b>E</b> GRIM N	<b>I</b> LSY
<b>MUKV</b>	<b>P</b> VYI VSYR ISD .	<b>E</b> LSKSD PI PSM KV	<b>R</b> NSTI	<b>N</b> LYTRSR .	<b>F</b> THADL H	<b>I</b> LSY
<b>TAV</b>	<b>P</b> VYI LNHPMEE .	<b>I</b> ERI QSSK I GFK I	<b>R</b> GKVL	<b>N</b> LYVKS K .	<b>A</b> GRDMH	<b>I</b> LSY
<b>TOV</b>	<b>P</b> VYI VSEK MEA .	<b>L</b> WEKEEE I LS FN LNR STI	<b>N</b> I S I A S A .	<b>S</b> GGRK MN	<b>I</b> LSY	<b>T</b> AGD GDL SP
<b>KAMV</b>	<b>P</b> IFLAKSTI YK .	<b>T</b> I I LDPSR LTL A	<b>H</b> GMTI	<b>N</b> LYVQETG I IGS YN RL DRFF H	<b>V</b> L S Y	<b>T</b> GRD T D VTEA
<b>SFTSV</b>	<b>P</b> VRIMERGF RI .	<b>R</b> E LQNP DEV KMR V	<b>R</b> GD I	<b>N</b> L SVT I	<b>E</b> GRVMN	<b>I</b> LSY
<b>UUKV</b>	<b>P</b> I F I VSEK I FR .	<b>P</b> ICWDPSK LE FRV	<b>R</b> GNTL	<b>N</b> LYTKEVNP G .	<b>A</b> GQRMF N	<b>I</b> LSY
<b>MUNV</b>	<b>P</b> VFTI RERMTD .	<b>L</b> H FVKTED I CM KV	<b>R</b> GSTI	<b>N</b> LF I P F Q .	<b>R</b> SDMH	<b>I</b> LSY
<b>LACV</b>	<b>N</b> YYI TYRK DRH QF VY QI HSHE S I	<b>T</b> RRNEEHMA	<b>I</b> R TRI Y NE	<b>T</b> PVCVNVA EVDGDQ RIL	<b>I</b> RS I	<b>D</b> YLN ND I F S L


	1880	1890	1900	1910	1920	1930
<b>RVFV</b>	I .F KSI S D E G V A Q A L Q L F E	<b>R</b> PSNC	<b>V</b> R CES VAPKF .I S A I L E I CEG K R O .I R G I N R T R L .S E I V R I C S E S			
<b>GTV</b>	A .AAFLWSN KD .SFSFGK K	<b>E</b> PSCS	<b>W</b> ICLK TLD NW A .W SHAST LLA T KR K .T PG IN NEL M .G N I F R D C L E G			
<b>MUKV</b>	S .I A ALRK CED GLE D L L K R	<b>E</b> PTCS	<b>W</b> FNCKPL D I GM .V E A L A O V L D G R R S L P R H L D K E R L .S S I F K M S C E S			
<b>TAV</b>	I .M N .G R S A E A E M I R E L F S A	<b>E</b> PSKS	<b>W</b> FTSKL P TES .V R T L L K V A S G H Y S .T S T I D P E K L .S D L L K L C T E S			
<b>TOV</b>	V .L N I I LP ST ETC NV MR H Y T G R L I N S	<b>W</b> YCKE L E L RD .I R R L A K LY E D Q S S .Q S L L D M D K M .R E I V K I C T E T				
<b>KAMV</b>	S .A K L L S Q L G K .T D W F P S K E	<b>E</b> PTFS	<b>W</b> MTM R A L P I S T .V D T I L S R M E S N R I P G .F D F D K L .R V C L K D I L E S			
<b>SFTSV</b>	A .A A Y L W S N R D .L F S F G K K	<b>E</b> PSCS	<b>W</b> ICLK TLD NW A .W SHAS V L L A N D R K .T Q G I D N R A M .G N I F R D C L E G			
<b>UUKV</b>	N .A F K L M S L S P .R H K F H G R E	<b>E</b> PS TS	<b>W</b> ICMR AL P I S T .I D K L L E R I L N R E R I S G S I D N E R L .A E C F K N V M E S			
<b>MUNV</b>	C .L R S N D .P F C K D V S D M F Q H E	<b>E</b> PSKS	<b>W</b> MRC S S L P Y D F .T G A V L N L S E G K I K .R D H I D T K R L .R E I I K T C T E S			
<b>LACV</b>	S R I K V G L D E F A T I K K A H F S K .	<b>E</b> PS	<b>W</b> V S F E G P P I K T G L L D L T E L M K S Q D L L N L N Y D N I R N S N L I S F S K L I C E G			



119

120 **Figure S12. Amino acid sequence alignment of L proteins.**

121 The amino acid sequences of L Proteins from RVFV (DQ375406), GTV (YP\_009666941),  
 122 Mukawa virus (YP\_009666332), Tapara virus (YP\_009346035), Toros virus (YP\_009246447),  
 123 KAMV (YP\_009449450), SFTSV (YP\_006504091.1), UUKV (NP\_941973), Munguba virus  
 124 (YP\_009346010), and LACV (EF485038.1) were aligned using Clustal Omega <sup>2</sup>. Secondary  
 125 structures for RVFV L<sub>RNA</sub> protein and eight conserved motifs were displayed.



126

127 **Figure S13. Comparison of each corresponding domain of RVFV, SFTSV, LACV, and FluA**  
128 **polymerase.**129 For overall structure comparison, parts of structures of RVFV L<sub>RNA</sub> protein, SFTSV apo-L  
130 protein (PDB 6L42), LACV L protein complex (PDB 5AMR), and Influenza A polymerases (PDB  
131 4WSB) were shown side by side: (A) regions corresponding to influenza virus PA,  
132 (B) PB1-like regions and (C) PB2-like regions and (D) overall architectures. Colors correspond to Figure 2A.  
133134 **Movie S1. Changes in the overall conformation of polymerase caused by the presence and**  
135 **absence of RNA**

136

137

138

139


140

141

142      **References:**

- 143
- 144      1. Tan, Y.Z. et al. Addressing preferred specimen orientation in single-particle cryo-EM  
145            through tilting. *Nat Methods* **14**, 793–796 (2017).
- 146      2. Madeira, F. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic  
147            Acids Res.* **47**, W636–W641 (2019).
- 148


# Figures



**Figure 1**


In vitro enzymatic activity assays (A) SDS-PAGE profile of Rift Valley fever virus (RVFV) L protein. (B) Size-exclusion chromatogram of RVFV L protein. Absorbance curves for the sample at wavelengths of 260 nm and 280 nm. (C) Endonuclease activity assay. RVFV L protein (0.06  $\mu$ M) was incubated with 0.45  $\mu$ M of fluorescently labeled 30 nt PolyA RNA substrate at 30°C for 40 min in the presence of 10, 25, or 50 mM MnCl<sub>2</sub> or CaCl<sub>2</sub>. Reactions without protein, in the presence of EDTA or the known endonuclease-specific inhibitor 2,4-dioxo-4-phenylbutanoic acid (DPBA), were negative controls. All input is shown as red arrows in Figure C, D, and E. (D) In vitro polymerase activity assay. The endonuclease and polymerase inactivation site double mutant (D111A/D1133A) was added in the left lane as a negative control. Mutant

(D111A) was added in the middle and right lanes. These three lanes were incubated with the conserved 5' 20 nt of the M segment or/and a 20 nt template RNA named RNA\* (5' M: 5'-ACACAAAGACGGUGCAUUAA-3', RNA\*: 5'-UGUGUUUCUGGCCACGUUGA-3'). Replication products were detected by fluorescence (fluorescein-12-UTP). (E) Effect of metal ions ( $Mn^{2+}$  or  $Mg^{2+}$ ) and reducing agent (DTT or TCEP (Tris(2-carboxyethyl)phosphine)) on de novo RNA synthesis by endonuclease inactivation site mutant (D111A). The assay was performed with 5 mM  $MnCl_2/MgCl_2$  and 2.5 mM DTT/TCEP for 40 min at 30 $^{\circ}C$ .



**Figure 2**


Overall structure of the Rift Valley fever virus (RVFV) L RNA protein and conserved motifs (A) Schematic representation of the monomeric RVFV L RNA protein domain structure. (B) Cartoon representation of the RVFV L RNA protein. The structure is colored by domains using the same color code as in (A). 310 helices are colored in gray. (C) The RVFV L RNA protein B-factor map. A larger radius and red color represent high B-factor values and a smaller radius and blue color represent low B-factor values. (D) The arrangement of the conserved RdRp motifs in the RVFV active site colored in red, green, blue, purpleblue, yelloworange, magenta, forest, and teal for motifs A–H, respectively.




**Figure 3**

The fingertips loops of machupo virus (MACV) Lapo, LACV L complex, apo FluC polymerase, Rift Valley fever virus (RVFV) Lapo, and RVFV L RNA. The B-factor maps for (A) MACV (PDB 6KLD), (B) LACV (PDB 6Z8K), (C) Influenza C (FluC) (PDB 5D98), (D) RVFV Lapo, (E) RVFV L RNA. (A, B, E) Fingertips are conservative, while FluC's and LACV's fingertips are unstable, and their replication process requires 5' RNA. (F) Interaction of residues between fingertips and finger extension. The residue on the fingertips and the finger extension are colored green and yellow, respectively.

A




B



Variable  
Conserved




D




**Figure 4**

Conservation analysis for RVFV L protein (A) Sequence conservation analysis. The left figure displayed in surface mode is positioned at the same view as the middle figure. Two different views of the Rift Valley fever virus (RVFV) L protein displayed in ribbon mode and colored based on the residue conservation among family Phenuiviridae. The bottom color code bar is from low conservation (cyan) to high conservation (purple). Figures are colored using the Consurf server (<http://consurf.tau.ac.il/2016/>) based on a multiple sequence alignment including the sequences of Tapara virus (YP\_009346035), Toros virus (YP\_009246447), Arumowot virus (YP\_009010958.1), Adana virus (YP\_009227127.1), SFTSV (YP\_006504091.1), Uriurana virus (YP\_009346036.1), Punta Toro virus (YP\_009512941.1), Anhangaa virus (API68876.1), and Munguba virus (YP\_009346010.1). (B) Sequence conservation in the putative priming loop. (C) The priming loop and connecting regions are shown as ribbons colored in green (RVFV) and yellow (SFTSV and PDB 6L42). Two glycine residues (Gly1344 and Gly1345), which are important for an early stage of RNA synthesis, are shown as sticks. (D) Structural demonstration shows the interaction sites of the priming loop (green) and thumb (cyan) and thumb ring domains (yellow).



**Figure 5**

The entrance and exit channels of Rift Valley fever virus (RVFV), SFTSV, LACV and FluA polymerases. The template entry, NTP entry, template exit, and product exit channels of (A) RVFV L RNA protein, (B) SFTSV Lapo protein (PDB 6L42), (C) LACV L protein (PDB 6Z8K), (D) Influenza A polymerase (FluA) (PDB 6T0V) are colored in limegreen, yelloworange, salmon, and magenta, respectively. The colors of the RVFV L domains are the same as those used in Figure 2A.



**Figure 6**

Superposition of low-resolution ab initio model and rigid body model (A) The ab initio model is shown as light-gray spheres. PA-like, PB1-like, and PB2-like N-terminal domains of RVFV L protein are colored in green. The simulated PB2 C-terminal domain is colored in yellow. (B) Comparison of SAXS experimental data and calculated scattering profiles. Experimental data are represented in black dots. The data calculated from the RVFV L protein is in red.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [RVFVLvalidationreportsall.pdf](#)
- [movieS1.mp4](#)